At week 104 , albiglutide significantly reduced HbA1c compared with placebo ( -0.9 % [ -9.8 mmol/mol ] ; P < 0.0001 ) , sitagliptin ( -0.4 % [ -4.4 mmol/mol ] ; P = 0.0001 ) , and glimepiride ( -0.3 % [ -3.3 mmol/mol ] ; P = 0.0033 ) .